Skip to main content
Premium Trial:

Request an Annual Quote

Quest Diagnostics Posts 6 Percent Revenue Increase for Q3

NEW YORK (GenomeWeb) – Quest Diagnostics today reported that its third quarter revenues climbed 6 percent year over year as the firm beat analysts' expectations on the top and bottom line.

The clinical lab and diagnostics information services firm reported total revenues of $1.90 billion for the three months ended Sept. 30, up from $1.79 billion for the third quarter of 2013 and above consensus analysts' estimate of $1.87 billion.

It said that diagnostic information services revenue was up around 7 percent year over year, while test volume increased around 8 percent. Acquisitions contributed approximately 7 percent to revenues in the quarter and reduced revenue per requisition by approximately 1 percent.

Quest posted net income of $129 million, or $.88 per share, compared to $405 million, or $2.68 per share, in Q3 2013. Its EPS on an adjusted basis was $1.10, beating the consensus Wall Street estimate of 1.08.

Last year's Q3 included a one-time approximately $300 million gain, or $1.97 per share, on the sale of Quest's IP royalty rights for cancer drug ibrutinib.

Quest's SG&A spending increased 5 percent to $446 million from $423 million. The firm also recorded $24 million in amortization of intangible assets compared to $20 million in Q3 2013.

Quest finished the quarter with $170 million in cash and cash equivalents.

The company said that it expects FY 2014 revenue growth to be around 3.5 percent versus its previous guidance of between 2.5 percent and 3.5 percent. It also narrowed its guidance for adjusted EPS to a range of $4.03 to $4.07 from a previous range of $4.00 to $4.10. Analysts, on average, expect EPS of $4.05.

Steve Rusckowski, president and CEO of Quest, said the firm "continued to see improvements in underlying trends in pricing, volume, and revenue."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.